紫杉醇
医学
胶囊
佐剂
内科学
乳腺癌
化疗
不利影响
白蛋白
胃肠病学
辅助治疗
CD8型
存活率
癌症
阶段(地层学)
肿瘤科
免疫学
免疫系统
生物
古生物学
植物
作者
Xiaoyu Zhang,Huixin Li,Feng Wu,Dan Sun,Hengle Zhang,Lijun Jin,Xiaoning Kang,Zunyi Wang
出处
期刊:PubMed
日期:2023-03-01
卷期号:36 (2(Special)): 619-623
摘要
To investigate the impact of Xihuang Capsule combined with albumin-bound paclitaxel on the treatment of stage III breast cancer and T cell subsets, survival rate and adverse reactions. Totally 200 patients with stage III breast cancer were evenly randomized into control group (albumin-bound paclitaxel for chemotherapy) and observation group (Xihuang Capsules for adjuvant therapy based on the treatment of the control group). The RR and DCR of the observation group was markedly higher as compared to the control group (66.7% vs 28.6%; 80.9% VS 47.6%) (all P <0.05). After 4 weeks of treatment, the CD8+ in the two groups decreased, while CD3+ and CD4+ increased, and the change in observation group was more significant (all P<0.05). The observation group exhibited a better half-year, 1-year, 1.5-year and 2-year survival rates compared to the control group (81.0% vs 71.4%, 71.4% vs 57.1%, 57.1% vs 33.3% and 42.9%vs 19.0%) (all P<0.05). Adding Xihuang Capsule to adjuvant therapy with albumin paclitaxel chemotherapy benefits the patient's immunity and survival rate, with good efficacy and safety profiles.
科研通智能强力驱动
Strongly Powered by AbleSci AI